Skip to content
Biotechnology

OncoSil Medical Receives MDR Approval

OncoSil Medical Limited (ASX:OSL) 2 mins read
  • Media:

 Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) (“OncoSil” or “the Company”) is pleased to announce that it has received Medical Device Regulation (MDR) certification from BSI, the EU Notified Body. The certification includes the lifting of existing post-market restrictions. This milestone highlights the growing robust clinical evidence supporting the safety of the OncoSil™ device and marks a significant step forward for the company.

The removal of these post-market restrictions will have a transformative impact on OncoSil’s operations. By eliminating local ethics and hospital governance approvals, OncoSil simplifies the initiation of commercial treatments, enabling smoother operations and allowing teams to focus on advancing commercial activities. The removal of operational constraints is projected to yield significant cost savings over the next three years, which will be reinvested in growth initiatives and strategic advancements of the OncoSilTM device. Simplified approval pathways further accelerate market access, shortening sales cycles and expanding the reach of the OncoSil™ device across the EU and UK, enhancing patient access and driving commercial success.

MDR certification also provides a critical opportunity to re-submit our application to the Therapeutic Goods Administration (TGA) for approval in the Australian market, aligning with our commitment to improving global patient outcomes.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"Receiving MDR approval is a pivotal achievement for OncoSil Medical. It underscores the strength of our clinical evidence and the safety profile of the OncoSil™ device. With the lifting of post-market restrictions, we are now in a stronger position to streamline operations, focus on commercial growth, and accelerate market access across key European markets. Importantly, this milestone allows us to revisit opportunities in the Australian market, reinforcing our mission to bring life-changing treatments to more patients worldwide."


About us:

About OncoSil Medical
OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for longterm survival.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy. 

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com


Contact details:

For more information, please contact:

Mr. Nigel Lange
CEO & Managing Director
E: nigel.lange@oncosil.com
T: +49 30 300 149 3043

Mr. Christian Dal Cin
CFO & Company Secretary
E: c.dalcin@acclime.com
T: +61 3 9824 5254

Media & Investor Enquiries
Ms. Julia Maguire
The Capital Network
Media and Investor Enquiries
E: julia@thecapitalnetwork.com.au
T: +61 2 8999 3699

More from this category

  • Biotechnology, Business Company News
  • 19/02/2025
  • 10:39
Optiscan Imaging Limited (ASX:OIL)

Optiscan Imaging (ASX:OIL) reveals InForm(TM) imaging device for pathology

Highlights: • Optiscan reveals InForm™, its next generation microscopic medical imaging device specifically designed for pathology workflows. •InForm™ expands Optiscan’s product portfolio into the pathology market, marking a pivotal milestone in advancing the Company's strategic objectives. •InForm™ can be used in a variety of pathology settings, most notably in laboratory medicine, pathology practice, point-of-care and digital pathology. •InForm™ is designed to enhance the entire pathology workflow across a range of settings, enabling efficiencies and on-the-spot digital decision making for pathologists to improve diagnostic capabilities. Optiscan Imaging Limited (ASX:OIL) is pleased to announce the reveal of InForm™, a groundbreaking microscopic medical…

  • Biotechnology
  • 13/02/2025
  • 03:14
Monash University

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates…

  • Contains:
  • Biotechnology
  • 12/02/2025
  • 11:19
BTC Health Limited (ASX:BTC)

BTC announces CFO and Company Secretary appointment

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment ofSalesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025.This appointment reflects the underlying expansion of theBTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from 17 March 2025. Salesh joins BTC from Universal Biosensors Australia, where he was the Chief Financial Officer and Company Secretary for more than 18 years. He is a member of the Institute of Chartered Accountants, (CA) and Certified Practicing Accountants (CPA). BTC’s current Company Secretary,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.